Tokyo, Sept. 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062848) titled 'A retrospective study of High-VAF FANCD2 variants and oncogenic drivers in non-small cell lung cancer' on Sept. 8.

Study Type: Observational

Primary Sponsor: Institute - Saiseikai Matsusaka Municipal Hospital

Condition: Condition - Non-Small Cell Lung Cancer Classification by malignancy - Malignancy Genomic information - YES

Objective: Narrative objectives1 - To determine the oncogenic driver positivity in patients with NSCLC harboring high-VAF FANCD2 variants (VAF>=40%) using institutional tumor-only CGP data, and to exploratorily compare it with those without FANCD2 variants. Basic objectives2 - Others

Eligibility: Age-lower limit - Not applicable Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Patients diagnosed with NSCLC at our institution during the study period. Patients who underwent CGP using OCA v3 or OCA Plus as part of routine clinical care and whose analysis results are evaluable. Patients whose minimum required clinical data can be retrieved from medical records. Key exclusion criteria - Patients who underwent CGP exclusively for tumors other than NSCLC. Patients whose genomic alterations, such as gene mutations or fusions, are substantially uninterpretable due to inadequate specimen quality or other technical reasons. Patients who declined to participate in the study via opt-out, either by themselves or through their proxies. Patients deemed inappropriate for analysis by the principal investigator due to compromised data quality (reasons to be documented). Target Size - 75

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2026 Year 08 Month 12 Day Date of IRB - 2026 Year 08 Month 21 Day Anticipated trial start date - 2026 Year 08 Month 21 Day Last follow-up date - 2026 Year 08 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071948

Disclaimer: Curated by HT Syndication.